London: Extending the number of pregnant women given a common drug to boost thyroid hormone levels may lead to a reduced number of still-births, early caesarean sections and low-weight babies, says a new study.
“Our work raises the possibility of providing real benefits from using a safe, cheap and well established treatment by simply extending it to the number of pregnant women we treat,” said lead author of the study Peter Taylor from University of Cardiff in Britain.
The thyroid gland is an organ found in the base of the neck. It produces essential hormones that control the body’s metabolism — the way we use energy.
Thyroid hormones are also critical for foetal brain development, but babies cannot make any of their own until the second trimester and have to source all of it from their mothers.
Pregnant women with mild hypothyroidism have low levels of thyroid hormones. This can be treated with a hormone replacement drug called levothyroxine.
In this study, the researchers investigated whether pregnant women with mild hypothyroidism and their babies would also benefit from levothyroxine treatment.
They combined data from a thyroid screening study and linked it to routinely collected clinical data to study the effect of correcting borderline thyroid function on obstetric outcomes.
The researchers analysed over 13,000 women who were 12-16 weeks pregnant, 518 of whom had mild hypothyroidism.
Of these, 263 women received levothyroxine and the rest received no treatment.
They assessed the women’s pregnancy outcomes by measuring stillbirth rates, preterm delivery, length of stay at hospital, birth weight and the number of early caesarean sections.
They found that women with mild hypothyroidism treated with levothyroxine had a lower risk of giving birth to low weight babies and were also less likely to undergo an early caesarean.
Untreated women with mild hypothyroidism were more likely to have a stillbirth than women with normal thyroid function and no stillbirths occurred in the treated group.
The findings were presented at the Society for Endocrinology’s annual conference in Brighton, England.